Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Inhibrx reports Phase 1 single agent dose escalation results for INBRX-105 » 09:07
03/12/21
03/12
09:07
03/12/21
09:07
INBX

Inhibrx

$24.64 /

+1.45 (+6.25%)

The company stated,…

The company stated, "INBRX-105 is a precisely engineered multi-specific therapeutic candidate based on our single domain antibody platform that is designed to agonize 4-1BB selectively in the presence of programmed death ligand 1, a protein that is typically found in the tumor microenvironment and lymphoid tissues. The study is a first-in-human, multicenter, open-label, non-randomized, Phase 1 trial in patients with locally advanced or metastatic solid tumors. The trial is designed to determine the safety profile and identify the maximum tolerated dose and/or recommended Phase 2 dose of INBRX-105 administered as a single agent or in combination with Keytruda, a programmed death receptor-1 checkpoint inhibitor. Single agent dose escalation was completed with a total of 32 patients enrolled. We observed dose-limiting toxicities, which were consistent with immune related adverse events (for example, hepatitis, arthritis and myalgia/hyperthyroidism) at several dose levels and determined the 1 mg/kg dose level as the MTD of INBRX-105. Patients were not pre-screened for PD-L1 expression. Eight out of 18 evaluable patients (44%) receiving INBRX-105 at dose levels equal to or greater than 0.1 mg/kg achieved stable disease, with the greatest reduction in tumor volume observed to be 20% by RECISTv1.1. The longest duration on treatment with INBRX-105 was 41 weeks, or approximately nine and a half months. Notably, seven patients with stable disease tested positive for PD-L1 expression, with a minimum of 1% positivity as determined by immunohistochemistry (Range 1 to 95%), and the results of one patient are pending. Four of these eight patients were refractory to or progressed on prior PD-1 checkpoint inhibitors. We expect to achieve the maximal therapeutic benefit of INBRX-105 in combination with PD-1 checkpoint blockade. In our preclinical studies we observed that acute exposure to PD-L1 dependent 4-1BB agonism was sufficient to derive maximal anti-tumor activity when co-dosed with another PD-1 blocking agent at a target saturating dose. As such, a dose escalation cohort of INBRX-105 in combination with Keytruda is targeted to initiate enrollment during the second quarter of 2021 and we expect to announce initial data during the fourth quarter of 2021."

ShowHide Related Items >><<
INBX Inhibrx
$24.64 /

+1.45 (+6.25%)

INBX Inhibrx
$24.64 /

+1.45 (+6.25%)

02/03/21 Credit Suisse
Inhibrx price target raised to $44 from $28 at Credit Suisse
09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
INBX Inhibrx
$24.64 /

+1.45 (+6.25%)

  • 19
    Aug
Earnings
Inhibrx reports Q4 EPS (47c), consensus (54c) » 09:03
03/12/21
03/12
09:03
03/12/21
09:03
INBX

Inhibrx

$24.64 /

+1.45 (+6.25%)

Reports Q4 revenue…

Reports Q4 revenue $2.78M, consensus $990,000.

ShowHide Related Items >><<
INBX Inhibrx
$24.64 /

+1.45 (+6.25%)

INBX Inhibrx
$24.64 /

+1.45 (+6.25%)

02/03/21 Credit Suisse
Inhibrx price target raised to $44 from $28 at Credit Suisse
09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
INBX Inhibrx
$24.64 /

+1.45 (+6.25%)

  • 19
    Aug
Conference/Events
Inhibrx management to meet virtually with Jefferies » 10:00
03/08/21
03/08
10:00
03/08/21
10:00
INBX

Inhibrx

$26.71 /

+0.28 (+1.06%)

Virtual Meeting to be…

Virtual Meeting to be held on March 8 hosted by Jefferies.

ShowHide Related Items >><<
INBX Inhibrx
$26.71 /

+0.28 (+1.06%)

INBX Inhibrx
$26.71 /

+0.28 (+1.06%)

02/03/21 Credit Suisse
Inhibrx price target raised to $44 from $28 at Credit Suisse
09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
INBX Inhibrx
$26.71 /

+0.28 (+1.06%)

  • 19
    Aug
Recommendations
Inhibrx price target raised to $44 from $28 at Credit Suisse » 08:29
02/03/21
02/03
08:29
02/03/21
08:29
INBX

Inhibrx

$37.96 /

+3.99 (+11.75%)

Credit Suisse analyst…

Credit Suisse analyst Martin Auster raised the firm's price target on Inhibrx to $44 from $28 and keeps an Outperform rating on the shares. After conducting a deep-dive on alpha-1 antitrypsin deficiency and INBRX-101, the analyst sees potential for significant program derisking if INBRX-101 can maintain plasma AAT levels within the normal range with evidence the drug effectively accesses the lung. Depending on the magnitude of de-risking observed and expectations of product positioning, Auster could see NPV upside of up to $20-$40/share.

ShowHide Related Items >><<
INBX Inhibrx
$37.96 /

+3.99 (+11.75%)

INBX Inhibrx
$37.96 /

+3.99 (+11.75%)

09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
09/14/20 Credit Suisse
Inhibrx initiated with an Outperform at Credit Suisse
INBX Inhibrx
$37.96 /

+3.99 (+11.75%)

  • 19
    Aug
INBX Inhibrx
$37.96 /

+3.99 (+11.75%)

Hot Stocks
Inhibrx Inc trading resumes  09:37
01/28/21
01/28
09:37
01/28/21
09:37
INBX

Inhibrx

$30.67 /

-3.695 (-10.75%)

 
ShowHide Related Items >><<
INBX Inhibrx
$30.67 /

-3.695 (-10.75%)

INBX Inhibrx
$30.67 /

-3.695 (-10.75%)

09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
09/14/20 Credit Suisse
Inhibrx initiated with an Outperform at Credit Suisse
INBX Inhibrx
$30.67 /

-3.695 (-10.75%)

  • 19
    Aug
INBX Inhibrx
$30.67 /

-3.695 (-10.75%)

Hot Stocks
Inhibrx Inc trading halted, volatility trading pause  09:32
01/28/21
01/28
09:32
01/28/21
09:32
INBX

Inhibrx

$30.67 /

-3.695 (-10.75%)

 
ShowHide Related Items >><<
INBX Inhibrx
$30.67 /

-3.695 (-10.75%)

INBX Inhibrx
$30.67 /

-3.695 (-10.75%)

09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
09/14/20 Credit Suisse
Inhibrx initiated with an Outperform at Credit Suisse
INBX Inhibrx
$30.67 /

-3.695 (-10.75%)

  • 19
    Aug
INBX Inhibrx
$30.67 /

-3.695 (-10.75%)

Over a quarter ago
Hot Stocks
Inhibrx granted FDA Fast Track designation for INBRX-109 » 09:01
01/13/21
01/13
09:01
01/13/21
09:01
INBX

Inhibrx

$34.20 /

+1.29 (+3.92%)

Inhibrx announced the…

Inhibrx announced the U.S. FDA granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. INBRX-109 is a precisely engineered tetravalent single domain antibody-based therapeutic candidate that agonizes death receptor 5 to induce tumor selective programmed cell death. A potential registration-enabling Phase 2 study of INBRX-109 has been discussed with the FDA and will be designed as a randomized, blinded, placebo-controlled study in unresectable or metastatic conventional chondrosarcoma with progression-free survival as the primary endpoint. Inhibrx expects to start dosing patients in this potentially registration-enabling study in the second or third quarter of this year.

ShowHide Related Items >><<
INBX Inhibrx
$34.20 /

+1.29 (+3.92%)

INBX Inhibrx
$34.20 /

+1.29 (+3.92%)

09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
09/14/20 Credit Suisse
Inhibrx initiated with an Outperform at Credit Suisse
INBX Inhibrx
$34.20 /

+1.29 (+3.92%)

  • 19
    Aug
INBX Inhibrx
$34.20 /

+1.29 (+3.92%)

Earnings
Inhibrx reports Q3 EPS (77c), consensus (60c) » 16:16
11/13/20
11/13
16:16
11/13/20
16:16
INBX

Inhibrx

$19.99 /

+0.5 (+2.57%)

Reports Q3 revenue $5.9M,…

Reports Q3 revenue $5.9M, consensus $1M. Mark Lappe, Inhibrx's CEO commented, "Over the course of the next two years, we expect multiple data read-outs from our four clinical programs in the oncology and orphan disease space and to initiate new clinical programs. This additional debt line from Oxford extends our IPO proceeds and provides us greater optionality and the ability to complete these expected clinical milestones with appropriate runway cushion. We appreciate the strong support and our longstanding partnership from Oxford."

ShowHide Related Items >><<
INBX Inhibrx
$19.99 /

+0.5 (+2.57%)

INBX Inhibrx
$19.99 /

+0.5 (+2.57%)

09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
09/14/20 Credit Suisse
Inhibrx initiated with an Outperform at Credit Suisse
  • 19
    Aug
INBX Inhibrx
$19.99 /

+0.5 (+2.57%)

Hot Stocks
Inhibrx's chondrosarcoma candidate shows positive Phase 1 results » 16:19
11/11/20
11/11
16:19
11/11/20
16:19
INBX

Inhibrx

$19.08 /

+0.33 (+1.76%)

Inhibrx announced updated…

Inhibrx announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma. Chondrosarcoma is an orphan disease and bone cancer with approximately 2,800 new patients diagnosed annually in the U.S.and the EU. There are currently no therapeutics approved for the treatment of chondrosarcoma. Inhibrx's most advanced program, INBRX-109, is a precision-engineered, tetravalent DR5 agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. Of the 12 patients evaluable for efficacy within the ongoing chondrosarcoma expansion cohort to date, disease control was observed in 11 of 12 patients - 92% - and 8 of 12 patients - 67% - had a decrease in their tumor burden. Two of the patients achieved partial responses with reductions in tumor size of 60% and 32% as of October 2020. Based on these preliminary results, the observed disease control rate at the four-month follow-up was 8 of 12 subjects - 67% - with 7 of 12 patients continuing on study. The longest disease control duration observed to date for a patient in this cohort was 33 weeks, or approximately eight months. The safety and tolerability profile continued to be favorable with most patients, approximately 90%, experiencing no signs of hepatotoxicity. There have been no new serious or severe adverse events since Inhibrx's last safety update in July. The trial is ongoing and an additional 10 patient slots were added, per investigator requests, to the chondrosarcoma cohort.

ShowHide Related Items >><<
INBX Inhibrx
$19.08 /

+0.33 (+1.76%)

09/14/20
Fly Intel: Top five analyst initiations
09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
09/14/20 Credit Suisse
Inhibrx initiated with an Outperform at Credit Suisse
  • 19
    Aug
INBX Inhibrx
$19.08 /

+0.33 (+1.76%)

Initiation
Fly Intel: Top five analyst initiations » 10:15
09/14/20
09/14
10:15
09/14/20
10:15
ARNC

Arconic

$20.56 /

+1.45 (+7.59%)

, CZR

Caesars

$52.53 /

+2.4 (+4.79%)

, OSTK

Overstock.com

$69.40 /

+4.28 (+6.57%)

, INBX

Inhibrx

$18.22 /

+0.99 (+5.75%)

, GNRC

Generac

$181.63 /

+3.02 (+1.69%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arconic (ARNC) initiated with a Buy at Deutsche Bank. 2. Caesars (CZR) initiated with a Neutral at Goldman Sachs. 3. Overstock.com (OSTK) initiated with a Buy at Needham. 4. Inhibrx (INBX) initiated with a Buy at Jefferies as well as an Outperform at Evercore ISI and Credit Suisse. 5. Generac (GNRC) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

GNRC Generac
$181.63 /

+3.02 (+1.69%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

09/13/20 Deutsche Bank
Arconic initiated with a Buy at Deutsche Bank
09/09/20 Benchmark
Arconic assumed with a Buy at Benchmark
05/20/20
Fly Intel: Top five analyst initiations
05/20/20 Credit Suisse
Arconic initiated with an Outperform at Credit Suisse
CZR Caesars
$52.53 /

+2.4 (+4.79%)

09/14/20 Goldman Sachs
Caesars initiated with a Neutral at Goldman Sachs
09/09/20 JPMorgan
Caesars price target raised to $55 from $50 at JPMorgan
08/13/20 JPMorgan
Caesars resumed with an Overweight at JPMorgan
08/03/20 Deutsche Bank
William Hill upgraded to Buy from Hold at Deutsche Bank
OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

09/14/20 Needham
Overstock.com initiated with a Buy at Needham
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 BofA
Overstock.com initiated with a Neutral at BofA
09/04/20 BofA
Overstock.com initiated with a Neutral at BofA
INBX Inhibrx
$18.22 /

+0.99 (+5.75%)

09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/14/20 Evercore ISI
Inhibrx initiated with an Outperform at Evercore ISI
09/14/20 Credit Suisse
Inhibrx initiated with an Outperform at Credit Suisse
GNRC Generac
$181.63 /

+3.02 (+1.69%)

09/14/20 Argus
Generac initiated with a Buy at Argus
09/03/20 Roth Capital
Generac price target raised to $210 from $190 at Roth Capital
08/21/20 Baird
Generac price target raised to $202 from $165 at Baird
08/13/20 Canaccord
Generac demand levels likely to capacity, says Canaccord
OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

GNRC Generac
$181.63 /

+3.02 (+1.69%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

  • 19
    Aug
  • 12
    Aug
CZR Caesars
$52.53 /

+2.4 (+4.79%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

INBX Inhibrx
$18.22 /

+0.99 (+5.75%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

OSTK Overstock.com
$69.40 /

+4.28 (+6.57%)

CZR Caesars
$52.53 /

+2.4 (+4.79%)

ARNC Arconic
$20.56 /

+1.45 (+7.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.